Trial · NCT06235216
Sacituzumab govitEcan in THYroid Cancers
NCT06235216, Phase 2, Recruiting, Grupo Espanol de Tumores Neuroendocrinos
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sacituzumab govitEcan in THYroid Cancers. Trials, record NCT06235216. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06235216
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sacituzumab govitEcan in THYroid Cancers
- NCT number
- NCT06235216
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 42 participants, estimated
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Conditions
- Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
- Interventions
- Sacituzumab govitecan
- First posted
- 2024-01-31
- Last updated
- 2026-09-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Throughout the study period, approximately 42 months since the inclusion of first patient | percentage/proportion of patients with confirmed complete response (CR) or partial response (PR) as their overall best response throughout the study period. Objective responses will be assessed locally by the investigator according to RECIST, version 1.1 |
| Secondary | Disease control rate (DCR) | Throughout the study period, approximately 42 months since the inclusion of first patient | Percentage/proportion of patients with complete response (CR) or partial response (PR), according to ORR definition for the trial, or maintained stable disease (SD) as their overall best response, assessed by imaging follow-up (CT scan/MRI) and RECIST 1.1 criteria. Stable disease should be maintained for at least 4 months to be considered as a CBR event. |
| Secondary | Duration of response (DoR) | Throughout the study period, approximately 42 months since the inclusion of first patient | Time from first confirmed response (CR or PR), according to ORR definition for the trial, to the date of the documented PD as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Those patients with response and without PD or death event will be censored on the date of their last tumor assessment. |
| Secondary | Progression-free survival (PFS) | Throughout the study period, approximately 42 months since the inclusion of first patient | Time from first dosing date to the date of confirmed PD according to RECIST 1.1. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment. |
| Secondary | Overall survival (OS) | Throughout the study period, approximately 42 months since the inclusion of first patient | Time elapsed from the first dose of study treatment until death from any cause. We will assess the median OS, estimated by Kaplan-Meier. Patients alive and free of events at the date of the analysis will be censored at their last known contact. Survival will be assessed by recording patient status at each visit. Long term follow up to be performed at least every 6 months. |
| Secondary | Safety profile | Throughout the study period, approximately 42 months since the inclusion of first patient | Percentage/proportion of patients that experience adverse events classified by their type, severity and seriousness according to the National Cancer Institute's Common Toxicity criteria (NCI-CTCAE v5.0) scoring system. |
| Secondary | Patient self-reported quality of life (QoL) | Throughout the study period, approximately 42 months since the inclusion of first patient | Assessed at baseline and every 12 weeks until progression through the EORTC QLQ-C30 questionnaire. The questionnaire is a validated tool composed of 30 questions or items that assess QoL in relation to physical, emotional, social aspects. The questionnaire is structured in 5 functional scales (physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent). The scores obtained are standardized to 0-100. |
| Other | TROP-2 positive rate | Baseline | Determined centrally on most recent archival tumor samples collected at baseline. Percentage/proportion of patients considered positive for the expression of TROP-2 gene. Strong complete membranous staining in \>5% of cells was considered positive. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06235216
GET https://conductscience.org/api/trials/v1/NCT06235216/registered